Asset profile
NNC0537-1482
Peptide
Evidence outlook · lead readout
NCT06625307 · Healthy Volunteers, Heart Failure
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06625307: Participants were randomly assigned to drug or placebo under quadruple-blind conditions across escalating doses, a sound early-safety design, but the primary measure was the number of adverse events rather than a clinical outcome, and results have not yet been reported.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.